Date of Award

Fall 9-19-2025

Document Type

Open Access Thesis

Degree Name

Master of Medical Science (MMSc)

First Advisor

Jorge Moreno, MD

Abstract

Background: Hyperglycemia-related emergency department visits represent a serious and costly complication for individuals with type 2 diabetes. While metformin is the most commonly prescribed first-line medication, many patients require additional antihyperglycemic therapy. The effect of these combination therapies on emergency care for hyperglycemia remains uncertain.

Objective: To examine whether different antihyperglycemics combined with metformin affect the incidence rate of hyperglycemic-related emergency department visits compared to metformin monotherapy, and to explore effects on recurrence and all-cause mortality.

Methods: We conducted a retrospective cohort study of adults with type 2 diabetes in the Yale New Haven Health System from January 1, 2020, through December 31, 2023. Patients were categorized into five groups based on their home antihyperglycemic regimen during their initial hyperglycemic-related emergency department visit. Negative binomial regression assessed the primary outcome of hyperglycemia-related visit incidence rates. Logistic regression examined the secondary outcomes of recurrence and all-cause mortality

Results: A total of 472 patients were included. No statistically significant differences in hyperglycemic-related emergency department incidence rates were found between any metformin-antihyperglycemic combination therapy and metformin monotherapy. Depression was associated with a 24% higher incidence rate and 157% higher odds of recurrence. Metformin combined with a sodium-glucose cotransporter 2 inhibitor was associated with 83% lower odds in all-cause mortality compared to metformin monotherapy.

Conclusions: Antihyperglycemics with metformin did not reduce hyperglycemic-related emergency department incidence rates compared to metformin monotherapy. Depression was strongly associated with increased incidence and recurrence, while metformin with a sodium-glucose cotransporter 2 inhibitor was associated with lower all-cause mortality.

Comments

This thesis is restricted to Yale network users only. If you are off campus, please connect to the VPN to access the PDF. It will be made publicly available on 12/7/26.

Available for download on Tuesday, June 15, 2027

Open Access

This Article is Open Access

Share

COinS